The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer.
 
Steven Brad Maron
Stock and Other Ownership Interests - Calithera Biosciences
Honoraria - Clinical Care Options; MedEd; RMEI Medical Education
Consulting or Advisory Role - Basilea; Health Advances; Natera
Research Funding - Guardant Health (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bayer; Merck
 
Walid Khaled Chatila
No Relationships to Disclose
 
Henry S. Walch
No Relationships to Disclose
 
Ryan Ptashkin
No Relationships to Disclose
 
Shalom Sabwa
No Relationships to Disclose
 
Lilan Ling
No Relationships to Disclose
 
Rebecca Nagy
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
 
Marc Simmons
No Relationships to Disclose
 
Richard K. G. Do
Honoraria - ALK (I); Genentech (I)
Consulting or Advisory Role - DBV Technologies (I)
Patents, Royalties, Other Intellectual Property - UptoDate chapters on Food Allergy (I)
 
Viktoriya Paroder
No Relationships to Disclose
 
Neeta Pandit-Taskar
Honoraria - Actinium Pharmaceuticals; AstraZeneca/MedImmune
Consulting or Advisory Role - Illumina; progenics
Speakers' Bureau - Actinium Pharmaceuticals
Research Funding - Bayer Health; Bristol-Myers Squibb; Clarity Pharmaceuticals; Imaginab; Janssen; Regeneron
Travel, Accommodations, Expenses - Bayer
 
Geoffrey Yuyat Ku
Consulting or Advisory Role - Apexigen; Bristol-Myers Squibb; I-Mab; Merck Sharp & Dohme; Pieris Pharmaceuticals
Research Funding - Arog (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); MedImmune (Inst); Merck (Inst); Oncolys BioPharma (Inst); Pieris Pharmaceuticals (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Aduro Biotech; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Sharp & Dohme; Pieris Pharmaceuticals
 
David H. Ilson
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; IQvia; Lilly/ImClone; Macrogenics; Merck; Pieris Pharmaceuticals; Roche/Genentech; Taiho Pharmaceutical
 
Jaclyn Frances Hechtman
Honoraria - Bayer; Illumina; WebMD
Consulting or Advisory Role - Axiom Healthcare Strategies; Bayer; Cor2Ed
Research Funding - Bayer; Boehringer Ingelheim; Lilly
 
Taha Merghoub
Stock and Other Ownership Interests - Imvaq therapeutics
Honoraria - Leap Therapeutics; Pfizer
Consulting or Advisory Role - ImmunoGenesis; Immunos Therapeutics
Research Funding - Bristol-Myers Squibb; Surface Oncology
Patents, Royalties, Other Intellectual Property - inventor on patent applications related to work on oncolytic viral therapy, alphavirus-based vaccines, neo-antigen modeling, CD40, GITR, OX40, PD-1 and CTLA-4.
 
David B. Solit
Stock and Other Ownership Interests - Fore Biotherapeutics; Loxo; Scorpion Therapeutics; Vividion Therapeutics
Consulting or Advisory Role - BridgeBio Pharma; Illumina; Lilly; Pfizer; QED Therapeutics; Scorpion Therapeutics; Syros Pharmaceuticals; Vividion Therapeutics
 
Nikolaus Schultz
No Relationships to Disclose
 
Yelena Y. Janjigian
Stock and Other Ownership Interests - Rgenix
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Imugene; Jounce Therapeutics; Lilly; Merck; Merck Serono; Merck Sharpe and Dohme Corp.; Michael J. Hennessy Associates; Ono Pharmaceutical; Pfizer; Rgenix; Seagen; Zymeworks
Research Funding - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Lilly; Merck; Rgenix (Inst); Roche
Other Relationship - Axis Medical Education; Clinical Care Options; Paradigm; Research to Practice